Results 61 to 70 of about 17,734 (168)
Head &Neck, Volume 48, Issue 10, Page 2810-2820, October 2026.ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange +16 more
wiley +1 more source
, 1984 A randomized phase III study was carried out in 57 patients with metastatic melanoma treated with either dacarbazine (DTIC) given intravenously (IV) daily for 10 days using light protection, or a combination of vinblastine IV on days 1 and 2, bleomycin ...
G T Kennealey, J M Kirkwood, S D Luikart
core +1 more source
Spectrometric Results of Process Variations in Dacarbazine
, 2022 Intra-lot and inter-lot variability in dacarbazine was detected in the Drug Quality Study (DQS) using Fourier transform near-infrared spectrometry (FTNIR). One vial of six vials sampled from Fresenius Kabi Lot 6125612 appeared 7.8 SDs from the center of
Philip Almeter (11325969) +5 more
core +1 more source
Effect of Amygdalin on Murine Melanoma Cancer Cell Line and Normal Human Fibroblast Cells [PDF]
Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2023 Background and Objectives: Melanoma is the most aggressive and fatal type of skin cancer caused by the uncontrolled proliferation of melanocytes. The ineffectiveness of existing therapies has encouraged researchers to use herbal medicines. Amygdalin is a
Azam Moslehi +3 more
doaj
MedComm, Volume 7, Issue 10, October 2026.Liver metastasis is a key driver of immune tolerance in patients with melanoma receiving immune checkpoint inhibitor therapy. This single‐arm phase II trial prospectively investigated the efficacy and safety of co‐ablation combined with sintilimab for liver metastatic melanoma.
Lujun Shen +11 more
wiley +1 more source
Cancer Reports, Volume 9, Issue 9, September 2026.ABSTRACT Background Salivary duct carcinoma is an aggressive salivary gland malignancy in which systemic therapy is often guided by androgen receptor and HER2 status. Treatment options are limited for HER2‐negative disease after progression on androgen‐deprivation therapy and chemotherapy, particularly when active central nervous system (CNS ...
Guang‐Liang Chen +5 more
wiley +1 more source
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study [PDF]
, 2019 BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. METHODS: Patients >/=18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS /=2 prior treatment regimens ...
Benson, Charlotte +33 more
core +1 more source
Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model [PDF]
Acta Cirúrgica Brasileira, 2017 Purpose: To evaluate the efficacy of nivolumab and comparison with dacarbazine (DTIC) on peritoneal carcinomatosis of malignant melanoma in mouse model.
Ozgul Duzgun +4 more
doaj +1 more source
Food Frontiers, Volume 7, Issue 5, September 2026.Cinnamaldehyde derived from Cinnamomum species exerts multitarget anticancer effects by promoting oxidative stress, mitochondrial dysfunction, apoptosis, cell‐cycle arrest, autophagy, and epigenetic changes, and by suppressing mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt ...
Gervason Moriasi +6 more
wiley +1 more source
DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy
MedComm, Volume 7, Issue 9, September 2026.This review synthesizes the expanding biology of PAMPs and DAMPs, from their molecular sources and sensing mechanisms to regulatory networks that govern inflammation and homeostasis. Spanning from classical immune activation to trained immunity and interorgan communication, we highlight the interplay between PAMPs and DAMPs and their context‐dependent ...
Xuanxuan Yu +6 more
wiley +1 more source